CSI Market
Sign In | Register

Akero Therapeutics Inc (AKRO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access AKRO quarterly Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Akero Therapeutics Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2024)
12 Months 		(Dec 31 2023) (Dec 31 2022) (Dec 31 2021) (Dec 31 2020)
Operating Activities
Income-252.06
Depreciation & amortization0.02
Amortization of Other Assets0.61
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation29.70
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.50
Shares Issued In Connection With Exclusive License Agreement-
Acquisitionoftechnologyinconnectionwithamgenagreementoperatingactivities-
Issuance Date Fair Value Of Anti Dilution Liability-
Change In Fair Value Of Anti Dilution Right Liability-
Acquired In Process Research And Development Expense1.00
Noncash Operating Lease Expense-0.26
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable2.01
Increase (Decrease) in Accrued Liabilities18.60
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-17.35
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-12.87
Discontinued operations0.00
Net Cash flow from Operating Activities-230.11
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities-516.04
Real Estate Investments0.00
Acquisition Of Technology In Connection With Exclusive License Agreement-
Proceeds From Sale Of Marketable Securities-
Proceeds From Maturity Of Marketable Securities407.34
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development-1.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-109.71
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.84
Long-term debt - borrowings10.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock13.15
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net344.84
Proceeds From Early Exercise Of Stock Options In Exchange For Restricted Common Stock-
Proceeds From Short Swing Profits Disgorgment-
Proceeds From Short Swing Profits Disgorgement-
Proceeds From Issuance Of Common Stock Pursuant To Employee Stock Purchase Plan0.46
Proceeds From Issuance Of Common In A Follow On Public Offering-
Proceeds From Issuance Of Common Stock Pursuant To Atm Offering78.24
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities445.85
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-230.11
Total Cash Flow106.03
4 historic quarters locked

Sign in to unlock the full Akero Therapeutics Inc cash flow history.

Sign In Create Free Account

About Akero Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20241231)
  • Filed with the SEC: February 28, 2025
  • Source: akro-20241231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-25-029514

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License